For the Keap1-Nrf2 pathway, halofuginone was reported to be able to deplete all Nrf2 in cells by inhibiting all protein synthesis, thus reducing the drug resistance of tumour cells in vivo and in vitro [116]. This evidence concerns the gene NFE2L2 and neoplasm.